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Treatment of bone fragility in patients with
diabetes: antiresorptive versus anabolic?
Meghna Shah a, Anusha Veeravanallur Appuswamy a, Sudhaker D. Rao b,
and Ruban Dhaliwal a

Purpose of review
The pathogenesis of bone fragility in diabetes has not been fully characterized. The antifracture efficacy of
available therapies remains unproven in patients with diabetes. We aim to collate current evidence of the
treatment of diabetic bone fragility, and to provide a rationale for considering optimal therapeutic option in
patients with diabetes.
Recent findings
The antifracture efficacy of antiresorptive and anabolic therapies is well established in patients without
diabetes. Studies in patients with osteoporosis have shown that anabolic therapies lead to faster and larger
benefits to bone mineral density and offer greater protection against fracture than antiresorptive therapies.
Available data suggest that antiresorptive and anabolic therapies have similar effect on bone density and
fracture risk reduction in patients with and without diabetes. However, the evidence in diabetes is limited to
observational studies and post hoc analyses of osteoporosis studies.
Summary
There are no specific guidelines for the treatment of bone fragility in patients with diabetes. We offer a
rationale for use of anabolic therapies in diabetes which is a low bone formation state, in contrast to
postmenopausal osteoporosis that is characterized by increased bone turnover. Prospective studies
evaluating the effect of available therapies on bone quality and fracture outcomes in patients with diabetes
are needed.
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INTRODUCTION
Diabetes and osteoporosis are common chronic conditions in older adults. The global prevalence of
diabetes mellitus is estimated to be 463 million [1].
Recent data suggest that the estimated prevalence of
osteoporosis in individuals with type 2 diabetes (T2D)
has increased from 3.1% to 6.1% between 2005 and
2014 [2]. Both type 1 diabetes (T1D) and T2D are
associated with an increased risk of hip fractures of up
to 33% [3 ]. Hip fractures correlat with higher mortality in those with diabetes compared to those without diabetes [4]. Findings of a large cohort study
indicate that this increased risk of fractures begins
in childhood and extends across the lifespan of
patients with T1D [5]. Further, fracture risk assessment in diabetes is challenging. The observed
changes in bone mineral density (BMD) in patients
with T1D and T2D fail to fully explain the increased
fracture risk, since BMD is only modestly reduced in
patients with T1D [6] and is usually normal or even
higher in patients with T2D [7] than in those without
&&

diabetes. Therefore, while BMD remains a strong
predictor of fractures in patients with diabetes,
BMD measurements alone tend to underestimate
fracture risk in this population [6,8,9].
The bone deficits observed in patients with diabetes and the underlying mechanisms that cause
these deficits have not been fully elucidated. Alterations in bone quality and bone strength of patients
with diabetes are the detrimental consequences of
insulin deficiency or resistance, hyperglycemia,
advanced glycation of bone matrix proteins, excess
cytokine production, and low bone turnover [10–
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KEY POINTS
 The bone fragility observed in patients with diabetes is
predicated on low bone turnover, impaired bone
material properties, and reduced bone quality.
 There are no randomized controlled trials that have
compared the efficacy of antiresorptive and/or
anabolic therapies on bone density, turnover, strength,
or fracture outcomes in patients with type 1 or type
2 diabetes.
 In the context of bone mineral density that is discordant
to the increased fracture risk, and low bone turnover,
anabolic therapies have a potential benefit for the
treatment of bone fragility in patients with diabetes.
 Prospective studies focused on the determinants of and
treatment for the bone fragility in patients with diabetes
are needed for developing an optimal approach to the
management of bone health in these patients.

12]. Other specific diabetes-related factors, such as
increased risk of falls due to retinopathy and neuropathy and peripheral vascular disease, may also
contribute to the greater fracture risk in these
patients [9–13].
The antifracture efficacy of osteoporosis medications is well established in individuals without
diabetes [14]. In contrast, there remains uncertainty
with regard to the role of antiresorptive versus anabolic therapies in the treatment of bone fragility
within the context of diabetes. Herein, we review
the available data on the efficacy of antifracture
therapies in patients with diabetes to guide optimization of bone health in this growing population.

ANTIRESORPTIVE THERAPIES
Antiresorptive agents reduce osteoclast-mediated
bone resorption throughout the treatment period
resulting in increased BMD, with a plateau effect in
response after 2–3 years of treatment [15,16]. The
net result is a reduction in fracture risk. Histomorphometry studies have demonstrated that in T1D and
T2D, bone turnover is low with a lower bone formation rate in patients with fractures or with diabetic
microvascular complications [17–21]. These findings have raised concerns that antiresorptive therapy may not be as effective in preventing bone loss
and reducing fracture risk in patients with diabetes
and may even further suppress bone turnover [22].

Antiresorptive therapy in type 1 diabetes
The prevention and treatment of bone fragility in
patients with T1D has become more clinically
2
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relevant with the rising life expectancy in these
patients. There is a dearth of data on the efficacy
of antiresorptive therapy in T1D. Studies have demonstrated lower bone formation and increased osteoblast apoptosis in T1D [17,18]. In a preclinical
study in which insulin-deficient mice had a lower
bone formation rate at baseline than control mice,
osteoblast apoptosis was decreased, and the bone
formation rate was further reduced in insulin-deficient mice following treatment with alendronate
[22]. Interestingly, the decrease in osteoblast survival in treated diabetic mice was similar to that in
nondiabetic controls, and the difference in bone
formation rate between treated diabetic mice and
treated control mice was not significant. A few
clinical studies have investigated the effects of antifracture treatment in patients with T1D. An observational study comparing the effect of risedronate
and conventional treatment (calcium þ vitamin D
supplementation) over a 12-month period in 52
participants with T1D reported a significant increase
in BMD at the spine and hip and in bone formation
markers [23]. In a large Danish case-control study
that included T1D and T2D patients, the fracture
risk reduction at spine, hip, and forearm following
alendronate therapy was similar to the risk reduction in those without diabetes [24], regardless of the
type of diabetes.
There are no studies that have investigated the
antifracture efficacy of denosumab, a human monoclonal IgG2 antibody that binds and inhibits
RANKL, in patients with T1D.

Antiresorptive therapy in type 2 diabetes
In contrast to the paucity of data in patients with
T1D, more information about bone health management in patients with T2D is available. A post hoc
analysis of three 48-week randomized control trials
(RCTs) in patients with (n ¼ 52) and without
(n ¼ 832) T2D showed that risedronate had similar
effects on markers of bone resorption and formation
and on lumbar spine BMD in both groups [25]. A
post hoc analysis of the Fracture Intervention Trial
(FIT) showed that, compared to placebo, alendronate decreased bone turnover markers (circulating
levels of C-terminal telopeptide and bone-specific
alkaline phosphatase) and improved BMD in
women with T2D [26]. The positive effect of alendronate in the T2D cohort was similar to that observed
in the nondiabetic group. One small observational
study also showed no between-group differences in
spine BMD response following treatment with
alendronate in postmenopausal women with and
without T2D [27]. With regard to fracture risk reduction, a post hoc analysis of two large RCTs (FIT and
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the Health Outcomes and Reduced Incidence with
Zoledronic Acid Once Yearly Pivotal Fracture Trial)
estimated that in older women with T2D on bisphosphonate treatment, the relative risk of nonvertebral fractures was 0.52 (95% CI: 0.33–0.80)
and that of vertebral fractures was 0.34 (95% CI:
0.18–0.67), compared to those in the placebo group
[28]. Thus, evidence of the therapeutic benefit of
bisphosphonates in patients with T2D is limited to
post hoc analyses of RCTs and an observational
study, but no prospective RCTs have evaluated the
effect of antiresorptive therapies on fracture risk
reduction in patients with diabetes.
Similarly, evidence for the antifracture efficacy of
denosumab in T2D patients is limited to one post hoc
analysis. In the Fracture REduction Evaluation of
Denosumab in Osteoporosis every 6 Months (FREEDOM) trial and its 7-year extension, 266 women with
diabetes who received denosumab had higher BMD
compared to the 242 women with diabetes who
received placebo [29]. Further, those treated with
denosumab had significantly fewer new vertebral
fractures than the placebo group (1.6% versus 8%,
RR:0.20, 95% CI 0.07–0.61; P ¼ 0.001) but had an
increased risk of nonvertebral fractures (11.7% versus
5.4%, HR:1.94, 95% CI 1.00–3.77; P ¼ 0.046).
In summary, available evidence suggests similar
efficacy of antiresorptive therapy in patients with
and without diabetes, although data for T1D are
sparse and limited to post hoc or secondary analyses
of studies in which neither patients with T1D or T2D
were the focus population. Nonetheless, BMD is an
inadequate marker of fracture risk in diabetes, and
whether an increase in BMD translates into clinically meaningful fracture risk reduction in this population is not known. It is speculated that
antiresorptive treatments, by further reducing preexisting low bone turnover in patients with diabetes, may have a detrimental effect on bone quality;
although, an associated increase in fracture risk
remains to be established. A population-based study
of patients with diabetes (T1D and T2D) and ageand sex-matched controls showed that further
reduction in bone turnover by antiresorptive therapy is not associated with an increase in fracture risk
[24]. Notably, the patients with diabetes in this
study had good glycemic control, which may have
prevented detrimental effects of antiresorptive therapy on bone turnover and quality. Given the paucity
of data on antiosteoporosis therapies in diabetes, it
is prudent to treat bone fragility in T1D and T2D
patients based on available guidelines until more
data emerge [30]. Prospective studies investigating
bone remodeling, bone quality, and fracture outcomes in patients with T1D and T2D are needed.

ANABOLIC THERAPIES
Available anabolic treatments include parathyroid
hormone (PTH) analog, teriparatide and PTHrelated peptide (PTH-rp) analog, abaloparatide.
Intermittent administration of PTH stimulates both
osteoclast-mediated bone resorption and osteoblastmediated bone formation, resulting in high bone
turnover with a net gain in bone mass [31]. In
addition, anabolic agents activate the canonical
Wnt signaling pathway and significantly increase
both modeling- and remodeling-based bone formation, thereby causing a marked increase in bone
formation [32,33]. The pathophysiology of bone
fragility in patients with diabetes is characterized
by impaired differentiation and maturation of
osteoblasts and decreased bone formation. Thus,
in theory, osteoanabolic therapies should be superior to antiresorptive therapies in diabetes. However,
the literature on the efficacy and safety of anabolic
therapies in patients with diabetes is scarce compared to that for antiresorptive therapies.

Anabolic therapy in type 1 diabetes
In studies of insulin-deficient mouse models that
show a reduced BMD phenotype, treatment with
intermittent PTH results in increased BMD and bone
formation rate [34,35]. Similarly, intermittent PTH
administration in mice with diabetes has been demonstrated to improve trabecular bone structure and
strength through the anabolic effects of PTH on
osteoblast differentiation and improved osteoblast
survival [36]. Interestingly, the anabolic effects of
PTH on trabecular bone were observed independent
of BMD, which remained lower in mice with diabetes than in controls. In another study, short-term
treatment with PTH-rp restored bone mass and
remodeling in mice with diabetes to the levels similar to those in controls [37]. To date, there are no
clinical studies (observational or prospective) that
have assessed the efficacy of osteoanabolic treatment in patients with T1D. Further, post hoc analyses of data from osteoporosis RCTs are not feasible
because these studies primarily focused on investigating postmenopausal or age-related osteoporosis,
and patients with T1D are likely excluded from
these trials.

Anabolic therapy in type 2 diabetes
By contrast, the effect of anabolic therapies in
patients with T2D has been assessed in preclinical
and clinical studies, although studies are limited in
number. Evidence from rodent studies indicate that
PTH improves bone mass and skeletal homeostasis
in the setting of diabetes [38,39]. Teriparatide has

1752-296X Copyright ß 2021 Wolters Kluwer Health, Inc. All rights reserved.

www.co-endocrinology.com

3

Copyright © 2021 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.

CE: D.C.; MED/280409; Total nos of Pages: 6;

MED 280409

Parathyroids, bone and mineral metabolism

been demonstrated to increase osteoblast number
and function on trabecular bone in the vertebrae
and increase trabecular bone mass, BMD, and
mechanical strength of vertebrae [39]. Further, teriparatide was shown to improve cortical bone structure and BMD in this study.
The Direct Analysis of Nonvertebral fractures in
Community Experience (DANCE) study was an
observational study of patients treated with teriparatide for up to 24 months and followed for an additional 24 months after cessation of treatment [40].
Post hoc analyses of the DANCE study showed a
similar increase in BMD and reduction of fracture
risk in patients with T2D as in patients without
diabetes. Increase in the spine and total hip BMD
did not differ between groups; interestingly, the
increase in femoral neck BMD was significantly
greater in T2D patients than controls [41]. An integrated analysis of 4 prospective observational studies assessing the antifracture efficacy of teriparatide
in 8828 patients with osteoporosis and comorbidities showed that the relative reduction in clinical
fracture rate was greater in diabetic than in nondiabetic subgroups [42].
Abaloparatide, a PTH-rp analog, is a selective
activator of the PTH-1 receptor signaling pathway
that preferentially stimulates bone formation in a
short period with a concurrent lesser increase in
bone resorption [33,43]. For this reason, abaloparatide is appealing for the treatment of bone fragility
in patients with diabetes. Post hoc analysis of postmenopausal women with T2D from the Abaloparatide Comparator Trial In Vertebral Endpoints
(ACTIVE), a phase 3, double-blind, randomized,
placebo- and active-controlled trial [44], demonstrated a significant increase in BMD at all skeletal
sites, improvement in trabecular parameters, and
fewer nonvertebral fractures in treated participants
than in the placebo arm [45].

Newer anabolic therapies: anti-sclerostin
antibodies
The anabolic Wnt signaling pathway stimulates
osteoblast-mediated bone formation and prevents
osteoclast differentiation and function. Sclerostin, a
physiological Wnt inhibitor, is secreted by mature
osteoblasts and osteocytes. An antisclerostin monoclonal antibody has been developed as an osteoanabolic therapy. In diabetic animal models,
sclerostin antibody treatment has been shown to
enhance bone formation and quality by facilitating
osteoblast differentiation and bone mineralization
in insulin-deficient mice, and enhance bone mass at
the spine and femur with a final BV/TV higher in the
T2D mice compared to controls [46,47]. Treatment
4
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with sclerostin antibody also resulted in improvement in bone strength of similar magnitude in
diabetic and nondiabetic animals. In the ActiveControlled Fracture Study in Postmenopausal
Women with Osteoporosis at High Risk (ARCH),
romosozumab, an antisclerostin monoclonal antibody, increased bone formation and significantly
reduced vertebral and nonvertebral fractures compared to alendronate [48]. Romosozumab was
approved in 2019 for use in postmenopausal women
at high risk for fractures. Clinical data on the efficacy
of romosozumab in patients with diabetes are lacking. Considering the concern about increased cardiovascular risk as observed in phase 3 studies
comparing romosozumab to alendronate [49], a post
hoc analysis of diabetes subgroup may be informative before prospective studies of romosozumab can
be considered in this high-risk population.
Overall, pivotal anabolic trials and comparative
studies have demonstrated greater and faster antifracture efficacy with anabolic therapies than with antiresorptive therapies, providing a clear rationale for the
use of these medications in individuals at high risk for
fracture. In theory, osteoanabolic treatments should
be superior to antiresorptive therapies in patients with
diabetes, as treatment with anabolic therapy addresses
the underlying pathophysiology of reduced bone formation. Available evidence suggests favorable outcomes in patients with diabetes with the use of
osteoanabolic therapies (Table 1). Prospective studies
are required to further validate these findings, specifically in patients with diabetes, both T1D and T2D.
General principles of bone health
management
General principles for the preservation of bone
health and prevention of fragility fractures in
patients with diabetes should include universal recommendations on bone health while simultaneously addressing diabetes-specific factors that
contribute to increased fracture risk. Lifestyle interventions are recommended for both osteoporosis
and diabetes. Regular physical activity (weight bearing exercises) helps prevent bone loss and aids in
glycemic control. Vitamin D deficiency is prevalent
in patients with T1D and T2D; therefore, adequate
replacement with vitamin D supplements is often
required [50,51]. Patients should ensure adequate
calcium intake as well. Maintaining mineral homeostasis is particularly important in the presence of
diabetic nephropathy, as disruptions in mineral
metabolism can lead to secondary hyperparathyroidism that can further weaken bone integrity.
Microvascular complications in patients with diabetes are associated with reduced BMD, inferior bone
Volume 28  Number 00  Month 2021
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Table 1. Effects of osteoporosis medications on BMD and fracture risk in type 1 and type 2 diabetesa
Medications

Type 1 diabetes
BMD

Type 2 diabetes

Risk of fracture

BMD

Risk of fracture

Alendronate [24,26]

"

#

"

#

Risedronate [23,25]

"

NA

"

NA

Zoledronate [28]

NA

NA

NA

#

Denosumab [29]

NA

NA

"

#

Abaloparatide [44,45]

NA

NA

"

#

Teriparatide [40–42]

NA

NA

"

#

Romosozumab [48]

NA

NA

NA

NA

a
Only available evidence is from observational studies and posthoc analyses.
" increase, # decrease, NA not available, BMD bone mineral density.

quality, and increased fracture risk [12]. Adequate
glycemic control is recommended to reduce all
complications in diabetes [52]. Importantly,
patients should be counseled about fall prevention,
as patients with diabetes are at high risk for falls [53].
This increased risk is multifactorial in etiology. In
addition to diabetic complications such as neuropathy and retinopathy, both hyperglycemia and
hypoglycemia are associated with an increased risk
of fracture and falls [53,54]. Therefore, in older
adults or those with a high risk of hypoglycemia,
avoidance of sulfonylureas (which can cause drastic
hypoglycemia) and a less stringent glycemic target
are encouraged, as recommended by the American
Diabetes Association guidelines [52]. Finally, antihyperglycemic medications such as thiazolidinediones and canagliflozin (an SGLT2 inhibitor)
with an unfavorable effect on bone metabolism,
should be avoided in patients with diabetes and
bone fragility [30].

CONCLUSION
Current gaps in our knowledge of the mechanisms
causing bone fragility in diabetes and the lack of
prospective studies evaluating efficacy of antifracture therapies in patients with diabetes are barriers
to effective treatment of compromised bone health
in this population. Studies suggest similar efficacy of
bisphosphonates in patients with and without diabetes, and there is no concrete evidence against the
use of bisphosphonates in patients with diabetes.
The majority of patients with diabetes included in
the studies have been those with T2D. The efficacy
of antiresorptive therapy in T1D is lacking. Limited
evidence suggests that denosumab may be a preferred option for older patients with diabetes or for
those with compromised kidney function. In the
absence of randomized trials, the role of antiresorptive treatment in diabetes remains unproven.

Anabolic therapies increase bone formation and,
consequently, are more appealing in the setting of
a low bone turnover state observed in patients with
diabetes. The findings from mouse models, observational studies, and post hoc analyses of osteoanabolic therapies in patients with diabetes are
promising. Randomized controlled trials exploring
how different therapeutic approaches affect bone
structure, bone remodeling, and fracture outcomes
are needed to fully elucidate and validate the benefit
of anabolic therapies in diabetes.
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